Current status of aneuploidy testing in Drosophila.
Based on the literature on file at EMIC, 181 papers contained material on aneuploidy testing. Initial screening rejected papers providing no data, no negative control and/or poorly designed genetic schemes; 67 papers representing tests of 76 compounds were reported on. Statistical classifications were established as follows: (+)=a statistically significant difference at the 5% level between the treated and control frequencies; (-)=no significant difference at the 5% level when the number of offspring tested was sufficient to have identified an increase of 0.2% over the control with a power of 75%; I=inconclusive= (a) no significant difference at the 5% level but the number of offspring tested was below that necessary to detect an increase of 0.2% with a power of 75%; (b) the nature of apparent complete loss is undetermined; or (c) the nature of the germ cells sampled is not determined. Of the 76 compounds analyzed, calls were made on 34 compounds. 17/34 compounds were positive for chromosome gain (11/34 for chromosome gain and chromosome loss, 6/34 for chromosome gain only). 17/34 compounds were negative for chromosome gain (11/34 for chromosome gain and chromosome loss and 6 for chromosome gain only). Are any fo the compounds found to induce aneuploidy specific for aneuploid induction? 7 or the compounds positive for chromosome gain were positive in one or more tests assaying for other genetic endpoints, and no reliable data exists regarding results in other tests for the remaining 10 compounds; accordingly, the answer to the question awaits further work.
Zimmering
S
S
Mason
J M
JM
Osgood
C
C
D000782:Aneuploidy; D000818:Animals; D003433:Crosses, Genetic; D004331:Drosophila melanogaster / Q000187:drug effects / Q000235:genetics*; D005069:Evaluation Studies as Topic; D005260:Female; D008297:Male; D009152:Mutagenicity Tests / Q000379:methods; D009153:Mutagens / Q000494:pharmacology*
D009153:Mutagens